Icon Menu

Decoding the Biology of Resilience

The next era of medicine begins before disease.

Sen-Jam is a computational drug discovery and development company pioneering a new class of prevention-led therapeutics —working with the body’s innate immune intelligence to preserve resilience through advanced inflammatory resolution.

Earlier intervention. Safer solutions. More complete resolution.

Clinically validated. Built for scale.

Explore the science
43fee7ece36b5775ed6a58d27d0d6d77f0000450
Disease Is the Outcome.

Disease Is the Outcome.

Loss of Resilience Is the Process.

Across aging, chronic disease, recovery, and human performance, a common biology is at work: inflammation.
Long before symptoms appear, resilience is already being lost.

Most medicine begins after dysfunction emerges.

We believe the greatest opportunity lies earlier.

“The future of pharma isn’t about treating one disease at a time.
It’s about unlocking the biology that connects them all…”

Jackie Iversen, RPh, MS

Inventor, Co-Founder & Chief Clinical Officer

D3bb35ed65cf161658b30e15ce8d898df9ef632d

OUTCOMES

One Biology. Many Expressions of Resilience.

Inflammation shapes aging, recovery, chronic disease, and human performance.

By restoring immune balance early in the inflammatory response, Sen-Jam is building a platform designed to preserve resilience across diverse conditions and therapeutic settings without immunosuppression.

Restoring Immune Balance (NLR)

Significant reductions in NLR demonstrate improved coordination between innate and adaptive immune response

Accelerating Recovery

Higher rates of complete symptom resolution following biological stress and inflammatory challenge.

Preserving
Resilience

Reducing inflammatory burden while supporting the body’s natural ability to restore equilibrium.

Reducing Persistence

Addressing inflammatory processes associated with chronic symptoms, long-duration recovery, and disease progression.

Logo Color

Safety comparable to placebo. Clinically validated. Built for scale.

Longevity begins with resilience.

Prevention-led therapeutics designed to preserve resilience.

Explore our Technology

Redefining Medicine.

We believe resilience is one of the most valuable and least understood assets in human health.

By decoding the biology that connects aging, recovery, and chronic disease, Sen-Jam is building a new class of prevention-led therapeutics designed to preserve health before dysfunction becomes disease.

A future where resilience is measured, preserved, and protected.

Logo Color

223 Wall Street #130 Huntington, NY 11743

info@sen-jam.com

Youtube Twitter Instagram Facebook

2026 Sen-Jam. All Rights Reserved.

Media Inquiry

Leaving so soon?

Join us in revolutionizing how the world treats inflammation. Stay informed about our latest breakthroughs in pain relief, viral infections, and opioid withdrawal.

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-002C Treatment for SARSCoV-2 Infection

Development: IN PHASE II CLINICAL TRIALS

We believe SJP-002C offers the world the most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection. Since SARS-CoV-2 emerged in 2019, there’s been a frenzy of scientific research on many fronts to help us understand and deal with this virus.

While the Big Pharma giants have been touting the value of anti-virals, we believe the true culprit in regards to tackling a coronavirus infection is the runaway inflammation that results in disease progression (hospitalization) and ultimately organ damage (lung problems we so often see). Antiinflammatory drugs, including NSAIDS—non-steroidal anti-inflammatories—and antihistamines and our combination of these already proven safe agents holds the key to this kingdom. These small molecules, which have already been cleared as safe, can be very effective at calming certain, very reactive parts of the immune system while leaving other parts free to work. That means anti-inflammatories can be offered to more people with less risk than other post-exposure strategies.

International scientists agreed with our premise and wanted to partner with us in our phase II clinical trials, which we are currently engaged in. With these efforts, we are now free to explore their ability to reduce mild-to-moderate symptoms as well as the frequency of progression to severe cases. We are also interested in their ability to prevent long COVID symptoms from occurring, as we explore the relationship between long COVID and inflammation in the brain.

Therapeutic Pipeline

Icon Otc WhiteOver the Counter

SJP-001 Prevention of Veisalgia (Alcohol Hangover)

Development: Phase 1

A hangover is a group of unpleasant signs and symptoms that can develop after drinking alcohol. As if feeling awful weren’t bad enough, frequent hangovers are also associated with poor performance and conflict at work. In fact studies show that there are over a hundred billion dollars lost in productivity as a result of alcohol hangover every year in America.

As a general rule, the more alcohol you drink, the more likely you are to have a hangover the next day. But there’s no magic formula to tell you how much you can safely drink and still avoid a hangover. SJP-001 was designed to help not only treat the signs and symptoms of alcohol hangover, it actually prevents them to begin with. In human studies, SJP-001 has been shown to be effective and safe and is on the pathway to becoming the only FDA-approved agent for this ailment that has hindered societies for thousands of years.

Therapeutic Pipeline

Icon Otc WhiteOver the Counter

SJP-002 Symptoms Associated with Viral Respiratory Infections (including Coronaviruses)

Development: Preclinical

We believe SJP-002 offers the world the most potent, orally available anti-inflammatory a person could obtain OTC. Common colds and viral infections cause irritation and inflammation leading to excessive congestion, coughing, sneezing and headache. By reducing this excessive response, an individual can avoid sick days.

Coronaviruses are a family of viruses that can cause illnesses such as the common cold, severe  acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). In 2019, a  new coronavirus was identified as the cause of a disease outbreak that originated in China; known now as COVID-19.

Recalibrated to prescription strength, we believe SJP-002 could be utilized for the COVID-19 virus. We are in active clinical relationships and are extremely optimistic with early results.

Therapeutic Pipeline

OTC WhiteOver the Counter

SJP-003 Vaccine Administration

Development: Preclinical

Vaccination is the administration of a vaccine to help the immune system develop protection from a disease. Vaccines contain a microorganism or virus in a weakened, live or killed state, or proteins or toxins from the organism. In stimulating the body’s adaptive immunity, they help prevent sickness from an infectious disease.

It is well documented that any vaccine can cause side effects. For the most part these are minor (for example, a sore arm or low-grade fever) and go away within a few days. That said, however, solving for the unintended negative impact vaccinations have on people is available through the proprietary formulation found within SJP-003. When administered at the time of the vaccine shot, signs and symptoms are reduced or eliminated completely.

Therapeutic Pipeline

OTC WhiteOver the Counter

SJP-004 Arthritis

Development: Preclinical

Arthritis is an inflammation of the joints. It can affect one joint or multiple joints. There are more than 100 different types of arthritis, with different causes and treatment methods. Two of the most common types are osteoarthritis (OA) and rheumatoid arthritis (RA). The symptoms of arthritis usually develop over time, but they may also appear suddenly. Arthritis is most commonly seen in adults over the age of 65, but it can also develop in children, teens, and younger adults. Arthritis is more common in women than men and in people who are overweight.

Some of the most common symptoms involved with arthritis include swelling, joint pain and stiffness. Often range of motion will decrease as well as redness of the skin around the joint. Many people with arthritis notice their symptoms are worse in the morning. In order to solve for these painful, often debilitating symptoms, you need a pain reliever that doesn’t create additional problems down the line, like is often the case with opioid-based agents. SJP-004 is designed to help solve for the inflammation and aches involved with arthritis in a meaningfully safe manner. This helps millions of people rebound from the impact of Arthritis and experience a full strength vital lifestyle

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-006 Opioid Dependence

Development: Preclinical

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States. Opioid use disorder diagnosis is based on the American Psychiatric Association DSM-5 and includes a desire to obtain and take opioids despite social and professional consequences. Examples of opioids include heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction with addiction representing the most severe form of the disorder. The disease is harrowing for millions due to the physiological dependence the drug has on the person who takes it. Studies show within just a few days, someone taking opioids exhibits signs and symptoms of dependence. Mitigating dependence is one of the critical factors in turning the tides on the Opioid Epidemic. Our product has shown promising results in all three of the lock holds Opioids have on people who use them: Dependence, Tolerance and Withdrawal.

SJP-006 is designed to specifically address opioid dependence and by doing so, makes tapering off opioid pain killers a more readily available option to the millions who are prescribed opioids each year. This prevents massive destruction in terms of prolonged addiction, jeopardizing professional and personal lives and in some cases, leading to death.

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-005 Opioid Withdrawal

Development: Preclinical

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States. Opioid use disorder diagnosis is based on the American Psychiatric Association DSM-5 and includes a desire to obtain and take opioids despite social and professional consequences. Examples of opioids include heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction with addiction representing the most severe form of the disorder. One of the key factors that keep millions of people addicted to opioids is the fact that tapering and attempting to stop taking opioids is extremely challenging due to the harrowing impact of signs and symptoms involved with opioid withdrawal on the body. Mitigating withdrawal symptoms is one of the – if not the most important– critical factors in turning the tides on the Opioid Epidemic. Our product, SJP-005 has shown results in our pre-clinical studies to reduce signs and symptoms of withdrawal by 50%. This is a remarkable statistic, worthy of serious installation in the medical community to help combat the Opioid Crisis.

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-007 Opioid Tolerance

Development: Preclinical

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States. Opioid use disorder diagnosis is based on the American Psychiatric Association DSM-5 and includes a desire to obtain and take opioids despite social and professional consequences. Examples of opioids include heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction with addiction representing the most severe form of the disorder. The disease is harrowing for millions due to the physiological dependence the drug has on the person who takes it.

Opioid dependence paralyzes so many in the world is the fact that as your body physiologically becomes more and more reliant on an opioid to achieve pain relief, over time, the body requires higher doses of an opioid agent to obtain the same level of relief. This is referred to has Opioid Tolerance. We believe our product, SJP-007, helps lower individual tolerance factors to opioids, including OxyContin, morphine, oxycodone, opium, Vicodin, Demerol, hydrocodone, methadone, Suboxone, heroin, and tramadol. By lowering tolerance factors involved with opioid use disorder, more people can reverse the hold opioids have on their lives.